Cargando…
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system
BACKGROUND: Several biomarkers have been separately described to select patients for immunotherapy (IO), but few studies integrate these markers. Di Maio, EPSILoN and the plasma microRNA signature classifier (MSC), are three different clinico, biochemical and molecular markers able to independently...
Autores principales: | Prelaj, Arsela, Proto, Claudia, Lo Russo, Giuseppe, Signorelli, Diego, Ferrara, Roberto, Mensah, Mavis, Galli, Giulia, De Toma, Alessandro, Viscardi, Giuseppe, Brambilla, Marta, Lobefaro, Riccardo, Trevisan, Benedetta, Trovò, Francesco, Torri, Valter, Sozzi, Gabriella, Garassino, Marina Chiara, Boeri, Mattia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354114/ https://www.ncbi.nlm.nih.gov/pubmed/32676324 http://dx.doi.org/10.21037/tlcr-20-231 |
Ejemplares similares
-
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
por: Signorelli, Diego, et al.
Publicado: (2022) -
Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations
por: Ferrara, Roberto, et al.
Publicado: (2021) -
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort
por: Prelaj, Arsela, et al.
Publicado: (2019) -
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy
por: Prelaj, Arsela, et al.
Publicado: (2022) -
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients
por: Prelaj, Arsela, et al.
Publicado: (2023)